DoseMeRx vs InsightRX (2026)
The precision dosing shortlist, and it is a genuine one because both compute a dose for drugs where getting it wrong causes kidney injury or treatment failure. InsightRX is the more inspectable: the population pharmacokinetic models it runs are published rather than proprietary, so a pharmacy can read the science behind the recommendation, and it holds certified Epic marketplace integration plus a published analysis of more than 168,000 treatment courses. DoseMeRx is the better designed at the bedside: it shows the pharmacist how well the model fits this patient's measured concentrations, which is the disclosure that tells you when to distrust the answer, and it publishes the clearest data residency statement in the category alongside HITRUST certification. Neither is FDA cleared, which is normal here and worth stating plainly, since the dose is computed by software no regulator has reviewed.
- The interface shows how well the model actually fits this patient's measured concentrations alongside the recommended dose, which is the strongest oversight design in the category because it lets a pharmacist see when the model is struggling rather than only what it concluded.
- The residency and stewardship disclosure is the most specific here, naming the cloud provider and the region, and stating what happens to patient data, where competitors publish nothing at all.
- HITRUST certification is held and the company states it is the only Bayesian dosing platform carrying it, which is a checkable competitive claim rather than a badge, alongside the widest geographic footprint in the segment.
- The model stack is the most inspectable in this index. The population pharmacokinetic models are named and published rather than proprietary, so a pharmacy department can read the literature behind the dose the software proposes.
- Certified integration rather than asserted, with applications fully certified in the Epic marketplace and automatic import limited to the data the dosing calculation actually needs rather than bulk extraction.
- A published analysis of more than 168,000 treatment courses, which is the strongest governance artifact in the lane and the closest thing to post deployment monitoring anyone here has produced.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. DoseMeRx and InsightRX are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | DoseMeRx | InsightRX |
|---|---|---|
| Primary category | Medication Safety & Prescribing | Medication Safety & Prescribing |
| Founded | 2012 | 2015 |
| Headquarters | Houston, Texas, United States | San Francisco, California, United States |
| Website | doseme-rx.com | insight-rx.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards DoseMeRx its top capability grade on Autonomy and Oversight Model, AI Safety and PHI Stewardship and Deployment Model and Data Residency. Set against InsightRX, DoseMeRx grades higher on several axes, including Autonomy and Oversight Model, AI Safety and PHI Stewardship and Deployment Model and Data Residency. Its thinnest published disclosure sits on AI Governance and Bias Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards InsightRX its top capability grade on Model and Technology Transparency and EHR and Interoperability Depth. Set against DoseMeRx, InsightRX grades higher on several axes, including AI Centrality, Model and Technology Transparency and Clinical and Operational Evidence. Its thinnest published disclosure sits on Commercial Transparency. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose DoseMeRx or InsightRX?
On the axes where the AI Health Index separates them, DoseMeRx grades higher on several axes, including Autonomy and Oversight Model, AI Safety and PHI Stewardship and Deployment Model and Data Residency, and InsightRX grades higher on several axes, including AI Centrality, Model and Technology Transparency and Clinical and Operational Evidence. InsightRX leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do DoseMeRx and InsightRX differ most?
The widest separation the AI Health Index records between DoseMeRx and InsightRX is on Deployment Model and Data Residency, where DoseMeRx grades A and InsightRX grades C. That axis sits in the Integration and Deployment group, so it should carry the most weight for a buyer whose binding constraint is how the product lands in the stack already in place.
Where do DoseMeRx and InsightRX grade the same?
The AI Health Index grades DoseMeRx and InsightRX the same on several axes, including Model Supply Chain Disclosure, HIPAA and BAA Posture and Security Certifications and Trust Center. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have DoseMeRx and InsightRX not disclosed?
At the last review, at least one of DoseMeRx and InsightRX published thin or absent detail on AI Governance and Bias Disclosure and Commercial Transparency. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Neither vendor holds a United States device clearance and neither claims one, which is the settled position for therapeutic drug monitoring software generally, but it means the dose these products compute is not reviewed by a regulator. Neither publishes pricing.
The independent head to head comparison in this segment, published in Pharmacotherapy, included both platforms and did not find them equivalent across every drug and scenario tested, so ask each vendor how it performed for the specific agents your service uses rather than in aggregate. DoseMeRx publishes no performance reporting by age, sex, race, renal function band or body habitus, and neither vendor publishes a bias assessment.